Abstract: SA-PO892
Semaglutide as an Aid to Weight Reduction in Adults With Obesity and Advanced CKD
Session Information
- CKD: Clinical Trials and Pharmacoepidemiology
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials
Authors
- Bukhari, Sarah, Beaumont Hospital, Dublin, Ireland
- Cooney, Sarah, Beaumont Hospital, Dublin, Ireland
- Holland, John, Beaumont Hospital, Dublin, Ireland
- Alzayer, Husam, Cork University Hospital, Cork, Cork, Ireland
- Clarkson, Michael, Cork University Hospital, Cork, Cork, Ireland
- Conlon, Peter J., Beaumont Hospital, Dublin, Ireland
Background
Obesity is becoming more challenging in patients with chronic kidney disease. The efficacy and safety of the GLP-1 analogue semaglutide for weight loss in patients with and without diabetes has been demonstrated. However, there had been limited studies on the use of semaglutide in patients with advanced CKD.
Methods
In this retospective study using electronic healthcare records, we evaluated the efficacy and safety of semaglutide for weight reduction in addition to lifestyle intervention in patients with eGFR of <30 ml/min/1.73 m2 and a body mass index of >32 kg/m2. Paired t-test was performed and a p-value of<0.05 was considered statistically significant.
Results
Among the 14 patients included in this study, the mean percentage change in weight loss after three, six and nine months were 5.5%, 8.5% and 9.7%, respectively. After nine months, 7 patients (50%) achieved ≥5% weight loss. The most common reported adverse events were gastrointestinal, including nausea, vomiting and diarrhoea. Two patients discontinued semaglutide because of intolerable gastrointestinal effects. No serious adverse events were noted.
Conclusion
In this set of patients with obesity and advanced CKD, semaglutisde was safe, effective and led to significant reduction in weight.
Comparison of weight at baseline and post-treatment at three, six and nine months
| Time point (months) | Sample size (N) | Mean weight loss | Mean percentage change in body weight (%) | p-value | 95% confidence interval |
| 3 | 13 | 6.1 kg | 5.5% | < 0.001 | 3.68–8.61 |
| 6 | 10 | 9.3 kg | 8.2% | < 0.001 | 5.04–13.58 |
| 9 | 7 | 10.4 kg | 9.7% | < 0.001 | 7.34–13.50 |